Jounce Therapeutics Культура компании

Dr. Elizabeth G. Trehu, also known as Beth, M.D. has been the Chief Medical Officer of Jounce Therapeutics, Inc., since November 3, 2015. Dr. Trehu served as the Chief Medical Officer of Promedior, Inc. since October 15, 2012. Dr. Trehu served as Vice President, Product Development and Medical Affairs at Infinity Pharmaceuticals, Inc. since November 8, 2010. She has more than 25 years of experience in the pharmaceutical industry, including expertise in oncology and hematology and have played key roles advancing multiple products through clinical development and obtaining regulatory approval. She spent four years at Genzyme Corporation, where she began as vice president of oncology global medical affairs and held the position of vice president and general manager, hematology with global responsibility for Clolar??? (clofarabine), Campath??? and Fludara??? (fludarabine). From 2002 to 2006, she held positions of increasing responsibility in medical affairs functions at Millennium Pharmaceuticals, principally in support of Velcade??? (bortezomib). Dr. Trehu's career prior to industry included laboratory and clinical research in immunotherapy of cancer as an assistant professor at Tufts University School of Medicine and several years in private practice as a hematologist-oncologist at the Jordan Hospital Club Cancer Center. She was recognized as a '2012 Woman to Watch' by Mass High Tech. Prior to that, she was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program. Dr. Trehu holds an M.D. from New York University School of Medicine and an A.B. in English Literature from Princeton University.

Dr. James P. Allison, also known as Jim, Ph.D., founded Jounce Therapeutics, Inc. in 2012. Dr. Allison serves as a Professor of Immunology at the University of California, Berkeley. He is the Founder of Neon Therapeutics Inc. He has been Scientific Advisor at BioAtla, LLC since November 16, 2017. Dr. Allison serves as the David H. Koch Chair in Immunologic Studies and Attending Immunologist at Memorial Sloan-Kettering Cancer Center. He has made many contributions in understanding of the regulation of the early events in T-cell activation. He serves as Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research and the Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center (MD Anderson). He served as the Chairman of Department of Immunology at The University of Texas MD Anderson Cancer Center. Dr. Allison is an Investigator with the Howard Hughes Medical Institute, the Director of the Ludwig Center for Cancer Immunotherapy and the Chair of the Immunology Program at the Memorial Sloan-Kettering Cancer Center. He has a longstanding interest in mechanisms of T-cell development and activation and the development of novel strategies for tumor immunotherapy. His research led to the clinical development of ipilimumab (Yervoy???), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Dr. Allison serves was the first person to isolate the T-cell antigen receptor protein. He served as President of the American Association of Immunologists from 2001 to 2002. His notable discoveries in his distinguished career studying the regulation of T cell responses, are the determination of the T cell receptor structure and that CD28 is the costimulatory molecule that allows full activation of na??ve T cells and prevents anergy in T cell clones.??? His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models and launched the emerging field of immune checkpoint blockade therapy for cancer. He serves as a Member of Advisory Board of The Irvington Institute for Immunological Research. He received the Lasker-Debakey Clinical Medical Research Award in 2015. He serves as a Director of the Scientific Advisory Council at Cancer Research Institute, Inc. Ontario Institute For Cancer Research. Dr. Allison served as an Associate Director of the Scientific Advisory Council at Cancer Research Institute, Inc. He serves as a Member of Scientific Advisory Board at Cellerant Therapeutics, Inc. He served as a Member of Scientific Advisory Board at Heat Biologics, Inc. and Kite Pharma, Inc. He served as Member of Scientific Committee at Innate Pharma S.A. He served as a Member of Scientific Advisory Board of Cerus Corporation since May 2004. He has received numerous awards, including the 2001 Centeon Award for Innovative Breakthroughs in Immunology; the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology; and The AAI-Dana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. He is a Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Dr. Allison received his B.S. and his Ph.D. in Biological Sciences from the University of Texas. He did his postdoctoral fellowship in molecular immunology at Scripps Clinic and Research Foundation.

Ms. Kimberlee Cobleigh Drapkin, also known as Kim, CPA, has been the Chief Financial Officer at Jounce Therapeutics, Inc., since August 2015 and has been its Treasurer since February 2013. Ms. Drapkin owned a financial consulting firm where she served as the interim Chief Financial Officer for numerous early stage biotechnology companies, including Jounce. In this role she helped early stage companies establish their financial infrastructure, manage financial strategy and operations, raise capital, build relationships with the financial community and oversaw all other financial activities. She served as the Chief Financial Officer of DeuteRx, LLC. She served as Chief Financial Officer of EPIX Pharmaceuticals, Inc. from August 16, 2006 to July 2009 and also served as its Principal Accounting Officer until July 2009. Ms. Drapkin has more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning. She served as Chief Financial Officer of Predix Pharmaceuticals, Inc., since March 2, 2002. Ms. Drapkin served as Chief Financial Officer of Predix Pharmaceuticals Holdings Inc., from February 2005 to August 2006 and served as its Principal Accounting Officer. She served as senior positions at Millennium Pharmaceuticals, Inc. with leadership responsibility for financial reporting, technical accounting, Sarbanes Oxley compliance and internal audit from 1995 to February 2005. She served as an Auditor in the technology and life sciences audit practice at PricewaterhouseCoopers LLP, Boston. She led the technical accounting, external financial reporting and internal audit functions and served as project leader for its Sarbanes Oxley implementation program. Prior to Millennium, she served in several years in the technology and life sciences practice at PriceWaterhouse Coopers LLP. Ms. Drapkin is a graduate of Babson College, holding a B.S. in Accounting and is a Certified Public Accountant.

Dr. Thomas F. Gajewski, also known as Tom, M.D., Ph.D., Co-founded Jounce Therapeutics, Inc., in 2012. Dr. Gajewski is the director of Melanoma Oncology and a professor in the Ben May Cancer Institute. He is an Associate Professor in the Departments of Pathology and Medicine and the Ben May Institute and Leader of the Immunology and Cancer Program at the University of Chicago Cancer Research Center. He served as President of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research. He has been a Member of Supervisory Board at Aduro BioTech, Inc. since January 26, 2017. He served as Member of Clinical Advisory Board at Point Therapeutics Inc. Dr. Gajewski has been a recipient of the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research and is the recipient of the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy. His research interests include the role of the STING (Stimulator of Interferon Genes) pathway in immunity, the molecular and cellular regulation of T lymphocyte activation and differentiation and the application of this information in immune-based cancer therapy. Dr. Gajewski also has a fellowship in hematology/oncology from University of Chicago's Department of Medicine. His clinical research includes the regulation of anti-tumor immune responses, melanoma biology and immunotherapy of melanoma. Dr. Gajewski received his medical training, Ph.D. in Immunology and B.A. at the University of Chicago. He joined the faculty in 1997. Dr. Gajewski has published more than 200 papers in peer-reviewed journals on basic aspects of T cell biology, anti-tumor immunity and melanoma therapy. His post-doctoral studies were conducted on T cell activation and anti-tumor immunity, also at the University of Chicago as well as at the Ludwig Institute for Cancer Research in Belgium. He has M.D. from the University of Chicago Pritzker School of Medicine.

Mr. Hugh M. Cole has been Chief Business Officer & Head of Corporate Development at Jounce Therapeutics, Inc. since August 15, 2017. Mr. Cole served as the Chief Business Officer and Senior Vice President of ARIAD Pharmaceuticals, Inc. since March 2014. Prior to joining ARIAD, he spent seven years at Shire Pharmaceuticals, most recently as Senior Vice President of Strategic Planning & Program Management and as Global Franchise Head and before that, as Vice President of Business Development. Prior to joining Shire, Mr. Cole served as Vice President of corporate development for Oscient Pharmaceuticals and served as senior director, business development and strategy at Millennium Pharmaceuticals. Earlier in his career, Mr. Cole worked as a management consultant for The Wilkerson Group, a leading consultancy focused on life science companies. Previously, he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly Genome Therapeutics) and at Millennium Pharmaceuticals and its affiliates. He led numerous successful acquisitions both at Shire and Oscient. He started his career as an investment analyst at Fred Alger Management and then as a Principal at the Wilkerson Group, a consulting and advisory firm. Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.

Dr. Robert D. Schreiber, also known as Bob, Ph.D. is Founder of Neon Therapeutics Inc. Dr. Schreiber serveD as Scientific Adviser at Jounce Therapeutics, Inc. He serves as Member of Scientific Advisory Board at Meryx Inc. He is Co-Founder, Chairman of Scientific Advisory Board and Director at Igenica, Inc. He serves as Associate Director of The Scientific Advisory Council, Member of Fellowship Review Committee and Member of Investigator Award & Predoctoral Program Review Committee at Cancer Research Institute, Inc. He previously served as Member of Scientific Advisory Board at Cerimon Pharmaceuticals, Inc. Dr. Schreiber received his BA degree in Chemistry and PhD in Biochemistry from the State University of New York at Buffalo in 1968 and 1973 respectively.

Dr. Louis M. Weiner, M.D founded Jounce Therapeutics, Inc. in 2012. Dr. Weiner is the Member of the Advisory Board of Hackensack Meridian Health John Theurer Cancer Center at Hackensack University Medical Center since January 23, 2018. He serves as Director of Cancer Center at Lombardi Comprehensive Cancer Center. He serves as Associate Vice President of Georgetown University Medical Center. He serves as Chair, Department of Oncology, Georgetown University Medical Center. Dr. Weiner is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. He serves as Vice President, Global Safety with world-leading biotech Amgen. He serves as the Principal Investigator for Fox Chase Cancer Center at Eastern Cooperative Oncology Group (ECOG). He is at the forefront of efforts to develop antibody-based therapies of human cancer and is a pioneer in the use of antibody engineering to improve selective tumor targeting and to manipulate antibody-directed immune effector functions. Dr. Weiner served as Vice President of Translational Research of Fox Chase Cancer Center. He has been on staff at Fox Chase Cancer Center since 1984. He served as the Chairman of the Department of Medical Oncology at Fox Chase Cancer Center since 1994, where he held an endowed chair in medical science and was the driving force behind developing an immunotherapy laboratory and clinical program, as well as establishing the Center's medical oncology fellowship program. He serves as a Director of Lombardi Comprehensive Cancer Center. He served as a Director of Cell Pathways, Inc. since 1998. He serves as Member of Scientific Advisory Board at Immunome, Inc. He has been a Member of Scientific Advisory Board of Merrimack Pharmaceuticals, Inc. since July 2006. He serves as a Member of Scientific Advisory Board for Glycart Biotechnology AG (now Roche Glycart AG). He serves as a Member of Scientific Advisory Board at CytomX Therapeutics, Inc. and Celldex Therapeutics Inc. He served as a Member of the Clinical Advisory Board of Patrys Limited and Member of Scientific Advisory Board at Agenix Ltd. He served as a Member of Scientific Advisory Board at Symphogen A/S until June 6, 2017. He served as a Member of the Scientific Advisory Board of Twin Butte Energy Ltd. He served as a Member of Oncology Clinical Advisory Board of Idera Pharmaceuticals Inc. since July 2006. He was course co-director for the annual AACR/ASCO Clinical Methods Workshop. He serves as Chairman of the Francis L. and Charlotte G. Gragnani. He is the G. Morris Dorrance Jr. Endowed Chair in Medical Science. He founded and was Chair of Cancer Immunology Working Group of American Association of Cancer Research (AACR). He is Director, Georgetown Lombardi Comprehensive Cancer Center. Dr. Weiner is also serves on several journal editorial boards, including Cancer Research and Clinical Cancer Research. He is a Senior Member in the Division of Medical Sciences at Fox Chase Cancer Center. He serves on the NCI Board of Scientific Counselors and on the NExT Oversight Committee. Since 1995, he has been a Professor in the Department of Medicine, Temple University School of Medicine. He lectures extensively on targeted therapies for cancer and has organised numerous international meetings on antibody engineering and immunotherapy. He is Professor of Georgetown University Medical Center. Dr. Weiner has published more than 150 scientific papers and lectures extensively on targeted therapies for cancer. He was Fox Chase Cancer Center's principal investigator for the Eastern Cooperative Oncology Group (ECOG) from 1994 to 2002, a major national study group working to improve cancer treatment through clinical trials. He is Internationally recognized medical oncologist. He is accomplished researcher developing novel immunotherapy treatments in his laboratory. Dr. Weiner is recognized for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient's immune system to fight cancer using monoclonal antibodies and the use of functional genomics tools to improve the anti-tumor consequences of antibody-targeted therapy. In 2001, he received the Scientific Research Award from the American Cancer Society - Southeast Region. He has also received the Janssen Pharmaceutical Research Foundation's Award for contributions to the field of Receptor Targeted Therapy. He received his MD from Mount Sinai School of Medicine in 1977 and his BA with Honors in Biology from the University of Pennsylvania in 1973.Symphogen A/S

Dr. Drew M. Pardoll, M.D., Ph.D., is an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at Johns Hopkins University of Medicine. Dr. Pardoll is Member of Scientific Advisory Board at Immunomic Therapeutics, Inc. since December 2017. Dr. Pardoll is the Scientific Founder and Board Observer at Amplimmune, Inc. (formerly Amplimmune Immunology). Dr. Pardoll founded Jounce Therapeutics, Inc. in 2012. He served as a Board Observer of Aduro BioTech, Inc. He serves as the Chairman of Scientific Advisory Board at Aduro BioTech, Inc. and Compugen Ltd. He served as the Chairman of the Scientific Advisory Board at Cerus Corporation since May 2004. He serves as a Director of DNAtrix, Inc. He serves as the Director at Dracen Pharmaceuticals, Inc. He serves as Director of the Cancer Immunology in the Sidney Kimmel Comprehensive Cancer Center. He has been a Member of Scientific Advisory Board at FLX Bio., Inc. since May 31, 2017, Compugen Ltd. since January 2014. He serves as a Member of Scientific Advisory Council at Cancer Research Institute, Inc. He has been a Member of Advisory Board at ISA Pharmaceuticals B.V. since October 15, 2013. He serves as a Member of Scientific Advisory Board of Five Prime Therapeutics, Inc., Immunexcite, Inc., and Jennerex. He served as a Member of Scientific and Medical Advisory Board at Mojave Therapeutics, Inc. Prof. Pardoll serves as Director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins. He served as a Director at Amplimmune, Inc. He has served on the editorial boards of the Journal of the National Cancer Institute and Cancer Cell and has served as a Member of Scientific Advisory Boards for the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, the American Association of Clinical Oncology and the American Association of Cancer Research. He served as a Director at Aduro BioTech, Inc. He served as a Member of Scientific Advisory Board at Cerus Corporation since May 2004. For the past two decades, Dr. Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy and his program led the clinical development of the first anti-PD-1 antibody. Dr. Pardoll is an internationally recognized authority in cancer immunology and immunotherapy. He is noted for demonstrating the central role of GM-CSF in stimulating dendritic cells in vivo. In addition, he is a Co-Inventor of cytokine-gene-transduced tumor vaccines. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines. Dr. Pardoll has published over 300 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He completed his M.D., Ph.D. in 1982, Medical Residency and Oncology Fellowship at Johns Hopkins University.

Dr. Padmanee Sharma, also known as Pam, M.D., Ph.D. has been Scientific Advisor of BioAtla, LLC since November 16, 2017. Dr. Sharma founded Jounce Therapeutics, Inc. in 2012. Dr. Sharma serves as an Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. She serves as Director of the Flow Cytometry Facility in the Koch Center. Dr. Sharma serves as an Associate Professor in the Department of Immunology, Division of Cancer Medicine at the MD Anderson Cancer Center, is a faculty member of The University of Texas Graduate School of Biomedical Sciences and Co-Director of the Immunotherapy Platform. Previously, she served as Associate Clinical Director at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center. She iis a medical oncologist and immunologist, her research work is focused on investigating mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. She is the principal investigator of several immunotherapy clinical trials that illuminate immune responses and pathways critical for eliciting anti-tumor responses in cancer patients. She has been a Member of Scientific Advisory Board of Constellation Pharmaceuticals, Inc. since May 25, 2017. She serves as a Member of Scientific Advisory Board of Oncolytics Biotech Inc. She served as a Member of Scientific Advisory Board at Kite Pharma, Inc. She has received the ASCO Young Investigator Award, the MD Anderson Physician Scientist Award and ASCO Career Development Award and her research enabled her to compete successfully for the Doris Duke Clinical Scientist Development Award and the American Cancer Society Mentored Research Scholar Grant. Dr. Sharma has received numerous awards in her field including the MD Anderson Cancer Center 2012 Faculty Scholar Award. Dr. Sharma is also an investigator on awarded AACR/SU2C/CRI cancer immunotherapy dream team grant. Dr. Sharma holds Ph.D. in immunology and M.D. from Pennsylvania State University. She holds B.A. in Biology and M.A. in biotechnology from Boston University.